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Abstract
Background: The sodium-hydrogen exchanger regulatory factor 1 (NHERF1) binds to the main renal phosphate transporter
NPT2a and to the parathyroid hormone (PTH) receptor. We have recently identified mutations in NHERF1 that decrease renal
phosphate reabsorption by increasing PTH-induced cAMP production in the renal proximal tubule.
Methods: We compared relevant parameters of phosphate homeostasis in a patient with a previously undescribed
mutation in NHERF1 and in control subjects. We expressed the mutant NHERF1 protein in Xenopus Oocytes and in cultured
cells to study its effects on phosphate transport and PTH-induced cAMP production.
Results: We identified in a patient with inappropriate renal phosphate reabsorption a previously unidentified mutation
(E68A) located in the PDZ1 domain of NHERF1.We report the consequences of this mutation on NHERF1 function. E68A
mutation did not modify cAMP production in the patient. PTH-induced cAMP synthesis and PKC activity were not altered by
E68A mutation in renal cells in culture. In contrast to wild-type NHERF1, expression of the E68A mutant in Xenopus oocytes
and in human cells failed to increase phosphate transport. Pull down experiments showed that E68A mutant did not
interact with NPT2a, which robustly interacted with wild type NHERF1 and previously identified mutants. Biotinylation
studies revealed that E68A mutant was unable to increase cell surface expression of NPT2a.
Conclusions: Our results indicate that the PDZ1 domain is critical for NHERF1- NPT2a interaction in humans and for the
control of NPT2a expression at the plasma membrane. Thus we have identified a new mechanism of renal phosphate loss
and shown that different mutations in NHERF1 can alter renal phosphate reabsorption via distinct mechanisms.
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Introduction
The maintenance of normal serum phosphate concentration is
critical for many biological processes including bone mineraliza-
tion and cell function. The kidney plays a pivotal role in phosphate
homeostasis. It adapts urinary phosphate excretion to balance the
quantity of phosphate absorbed by intestine or stored by cells and
bone. Phosphate is filtered at the glomerulus and mainly
reabsorbed in the renal proximal tubule through the type 2a
sodium-phosphate cotransporter (NPT2a) and to a lesser extent
through the type 2c sodium-phosphate cotransporter (NPT2c) [1] .
The magnitude of renal phosphate reabsorption relies on the level
of expression of NPT2a at the apical plasma membrane of
proximal tubular cells. Defects in NPT2a activity, as observed in
patients with loss-of-function mutations of NPT2a or in mice with
NPT2a gene ablation, results in hypophosphatemia with reduced
capacity of the kidney to reabsorb phosphate (TmP/GFR) and
increases the risk of renal lithiasis or bone demineralization
[2,3,4,5]. Two hormones reduce NPT2a expression at the plasma
membrane: parathyroid hormone (PTH) and fibroblast growth
factor 23 (FGF23). PTH removes NPT2a from the apical plasma
membrane by stimulating cyclic adenosine monophosphate
(cAMP) production through PTH type 1 receptor (PTH1R).
The amount of cAMP produced in response to PTH in proximal
tubular cells is modulated by the sodium-hydrogen exchanger
regulatory factor 1 (NHERF1) [6,7].
NHERF1 is a protein with two structural domains named
PDZ1 and PDZ2. These domains bind to the carboxy-terminal
parts of transporters or receptors. Hence, NHERF1 binds to the c-
terminal extremity of PTH1R and decrease PTH-induced cAMP
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NHERF1 in patients with hypophosphatemia, low TmP/GFR
and normal serum PTH and FGF23 concentration [9]. The
mutations were located in the PDZ2 domain of NHERF1 or in the
inter-region domain. Contrary to wild type NHERF1 protein, the
mutant NHERF1 proteins were unable to control PTH-induced
cAMP production in renal cells in culture.
Co-immunoprecipitation experiments showed that NHERF1
also binds to the c-terminal part of NPT2a. This binding may
preferentially involve the PDZ1 domain of NHERF1 [10,11].
Several data suggest that NHERF1-NPT2a interaction is manda-
tory to maintain a proper expression of NPT2a at the apical
domain of proximal tubular cells. Hence, disruption of NHERF1
gene in mice decreased NPT2a expression in renal brush border
membranes [12]. However the complete invalidation of NHERF1
expression abrogates not only the NPT2a-NHERF1 interaction
but also the association of NHERF1-PTH1R. Manipulations of
NHERF1 that exclusively alter NPT2a-NHERF1 association are
lacking to support the physiological importance of this interaction.
We report here the characterization of a naturally occurring
NHERF1 mutation identified in a patient with a decreased
capacity of the renal tubule to reabsorb phosphate. We show that
this mutation impinges renal phosphate transport by a mechanism
distinct from that reported for previously identified NHERF1
mutants.
Methods
Objectives
We described the consequences of a previously unidentified
mutation in the PDZ1 domain of NHRF1 gene. We analyzed the
mechanism by which this mutation can impair renal phosphate
reabsorption.
Participants and ethics
The patients provided written informed consents to obtain
blood DNA samples for genomic DNA extraction in accordance
with French national guidelines. This study was approved by the
local ethic comitee: Comite ´ Consultatif de Protection des
Personnes en Recherches Biome ´dicales Bichat Claude Bernard.
Sequencing was performed on genomic DNA obtained from
patients who were referred to our clinical department for renal
assessment before initiating potentially nephrotoxic treatment for
psoriasis, or before heminephrectomy for living kidney donation,
or for examination of renal lithiasis or bone demineralization. In
these subjects we measured serum phosphate and PTH concen-
trations and calculated the TmP/GFR value using Walton and
Bijvoet nomogram [13].
Sequencing
Both strands of the coding region and the intron-exon junctions
of NHERF1 were sequenced by investigators who were unaware
of the clinical history and the biological parameters of the patients.
The sequences of the intronic primers used for the polymerase
chain reaction have already been published [9]. The PCR
products were sequenced with the use of the BigDye Terminator
Cycle Sequencing Ready Reaction kit (Perkin Elmer on an ABI
PRISM 3100 sequencer (Applied Biosystems). Both strands were
analyzed using the software program Sequencing Analysis
(Applied Biosystems) and Clustal W (Infobiogen). The nucleotide
position was numbered according to the starting point of the ATG
codon in the complementary DNA (cDNA) (sequence accession
number NM_004252).
Biochemical measurements of electrolyte and hormone concen-
tration were based on standard clinical laboratory procedures.
Plasma FGF23 concentration was measured with an Elisa assay
(Human FGF-23 (C-Term) ELISA Kit, Immutopics, Inc, San
Clemente, CA, USA).
Cell culture
Opossum kidney (OK) cells and Hela cells were obtained from
the American Type Culture Collection. OK cells were cultured in
DMEM/Ham’s F12 containing sodium bicarbonate, 14 mM;
Hepes, 20 mM pH 7.40; sodium selenite, 50 nM; L-glutamine,
2 mM; Insulin, 5 mg/ml; 5 mg/ml transferrine; Hydrocortisone;
defined bovine serum, 2.5% under a 5% CO2-containing
atmosphere.
HeLa cells were cultured in DMEM with glucose, 4.5 g/l;
Glutamine, 200 mM; Sodium Pyruvate, 1 mM; Hepes 20 mM
and defined foetal bovine serum, 5% under a 5% CO2-containing
atmosphere.
Plasmid construction
Wild type NHERF1 cDNA was inserted into pEF1-B plasmid
by PCR amplification, and subcloned into pEF1-B (Invitrogen)
plasmid using EcorV-Not1 enzymes. NHERF1 mutants were
generated from the wild type cDNA with the use of Quick Change
Site-directed Mutagenesis kit (Stratagene). All constructs were
verified by sequencing. Flag or GFP tags were inserted at the N-
extremity of the protein.
Cell transfections. Subconfluent cells were transfected with
the lipofectamine reagent and 0.5 mg/ml of NHERF1 vectors or
0.25 mg/ml of human SLC34A1 plasmid according to
manufacturer’s instructions (Invitrogen).
Expression in Xenopus laevis oocytes, Voltage-Clamp experi-
ments. Oocytes were surgically harvested from Xenopus laevis
obtained from Centre de Recherche de Biochimie Mole ´culaire
(CNRS Montpellier, France) with the agreement of the Comite ´
Re ´gional d’Ethique pour l’Expe ´rimentation Animale Ile de France
Paris Descartes. Wild type or mutant NPT2a or NHERF1 cDNAs
were introduced in the RNA expression vector pSP64T. RNA was
synthesized with the use of the Riboprobe in Vitro Transcription
System kit (Promega). Defolliculated oocytes were injected with
10 ng of wild type NPT2a (SLC34A1) RNA and 24 hours later
with 10 ng of NHERF1 RNA. Phosphate-induced current was
measured as previously described with an imposed holding
potential of 250 mV [4].
Phosphate uptake experiments. Radiolabeled phosphate
uptake was measured by incubating cells for 10 min in isoosmotic
transport medium containing or not Na and 0,5 mCi/ml
32P.
Cells were washed 3 times with cold medium (pH 7,4) and
solubilized with 0,5% triton X-100. The radioactivity of the lysate
was counted by liquid scintillation spectroscopy. Each assay was
performed in triplicate.
Intracellular cAMP content was measured in OK cells pre-
incubated for 30 min at 37uC, under a 5% CO2-containing
atmosphere in culture medium containing 3-isobutyl-1-methyx-
anthine, 1 mM and exposed afterwards to 10
27 M PTH, diluent
(negative control) for 5 min at 37uC, under a 5% CO2-containing
atmosphere. Total intracellular cAMP quantification was per-
formed using Cyclic AMP Competitive ELISA Kit (Thermo,
France) according to manufacturer’s instructions.
PKC activity was determined using the Promega SignaTECT
PKC Assat system, which contains a specific PKC substrate
(biotinylated Neurogranin28–43). This
32P-labeled substrate was
recovered with a streptavidin matrix according to the manufac-
turer’s instructions (Promega Corp. WI, USA).
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performed in HeLa cells transfected with pEF1-B empty plasmid,
NHERF1 wt or E68A mutant and NPT2a-peGFP, using Cell
Surface Protein Isolation Kit (Pierce) according to the manufac-
turer’s instructions.
Antibodies used. HRP-conjugated anti Flag M2 antibody was
purchased from Sigma chemical co. Anti NHERF1 antibody was
purchased from Santa Cruz biotechnology. Anti GFP antibody
was purchased from Chemicon (Millipore). Anti Na-K-ATPase
was purchased from Abcam.
Statistical analysis
statistical tests used are indicated where appropriate.
Results
Case report
The mutation was identified in a 71 year-old patient who was
referred to our clinical department for renal calcium lithiasis and
serum ionized calcium concentration in the upper normal values,
associated with hypercalciuria (Table 1). Serum phosphate
concentration and TmP/GFR were below the lower limit of the
normal values contrasting with serum PTH concentration within
the low normal range (Table 1). The study of the relationship
between TmP/GFR and serum PTH values in a group of 112
control subjects clearly showed that TmP/GFR was uncommonly
low in face of serum PTH concentration in this patient (Figure 1).
This difference was not explained by serum FGF23 concentration,
which was in the low range (Table1). Urinary cyclic AMP
excretion was normal. Serum FGF23 concentration was not
increased. Plasma concentration of 1,25 (OH)2 vitamin D was
slightly elevated. Thyroid hormone measurement discarded
hyperthyroidism. Bone mineralization was normal at the lumbar
spine (T-score 20.9) and slightly decreased at the radius (T-score
21.4) and at the hips (T-score 21.6). The patient exhibited no
other sign of proximal tubule dysfunction: glycosuria, aminoacid-
uria was absent and serum bicarbonate concentration was normal.
The diagnosis of impaired renal phosphate reabsorption was
retained. We sequenced both strands of the genes encoding the
renal sodium-phosphate co-transporters SLC34A1 (NPT2a) and
SLC34A2 (NPT2c) and found no mutation.
We sequenced the coding region and the intron-exon junctions
of the NHERF1 gene and identified a previously unreported
mutation. The patient had a c.203 A R C heterozygous transition
in exon 1, which substituted alanine for glutamic acid at position
68 (p.E68A) (figure 2 A). The alignment of the NHERF1 protein
sequence showed that glutamic acid 68 was highly conserved in
the NHERF1 PDZ1 domain throughout evolution and in the
PDZ1 domain of NHERF2 of various species (figure 2 B, C)
suggesting that it plays an important role in the function of this
domain. Furthermore this variant was not found in the 1000
genomes database (http://browser.1000genomes.org).
The patient had no relatives alive, consequently we could not
study the segregation of the mutation with a low TmP/GFR.
However to determine if this mutation could be present in subjects
with normal renal reabsorption of phosphate we sequenced
NHERF1 in a population of 112 subjects with normal TmP/
GFR and we did not find a single example of the E68A mutation.
We have previously reported, in patients with impaired renal
phosphate reabsorption, mutations in the NHERF1 protein that
induced an increase in PTH-induced cAMP production [9]. We
evaluated cAMP production in response to PTH in OK cells, a
model of renal proximal tubular cells. OK cells were transfected
with a control plasmid or with a plasmid containing either the wild
type cDNA, or the mutant E68A, or previously identified mutants
(R153Q or E225K). PTH markedly stimulated cAMP synthesis in
OK cells expressing the control plasmid. As previously observed,
cAMP production was blunted in cells expressing wild type
NHERF1 cDNA and this effect was not observed in the presence
of R153Q or E225K mutants. By contrast cAMP stimulation was
similarly decreased in cells transfected with the E68A mutant or
the wild type NHERF1 cDNA (Figure 3A). Since PTH receptor
can also signals through PKC pathway we also compared PTH-
stimulated PKC activity in OK cells transfected with empty
plasmid or with wild type NHERF1 or the E68A mutant
(Figure 3B). OK cells were stimulated with two concentration of
PTH. PTH-induced PKC activity was similar in all conditions
(Figure 3B). To make sure that the E68A mutant did not interfere
with another PTH-induced signaling pathway that could inhibit
phosphate uptake we compared the inhibitory effect of PTH at
two concentrations in OK cells expressing wild type NHERF1 or
the E68A mutant (Figure 3C). As expected PTH inhibited
phosphate transport at both concentrations with a similar
magnitude under all experimental conditions.
Figure 1. Relationship between serum PTH concentration and
the capacity of kidney to reabsorb phosphate normalized for
the glomerular filtration rate (TmP/GFR) in 112 control
subjects (diamonds). The patient with the mutation in NHERF1 gene
is represented by a circle.
doi:10.1371/journal.pone.0034764.g001
Table 1. Biochemical data of the patient.
Patient Normal Range
Serum Phosphate (mmol/l) 0.83 0.85–1.40
TmP/GFR (mmol/l) 0.75 0.75–1.40
Serum ionized calcium (mmol/l) 1.28 1.15–1.30
Serum PTH (pg/ml) 19 11–60
Serum FGF23 (RU/ml) 18 ,120
Serum 1,25-dihydroxyvitamin D (pg/ml) 48 16–42
GFR (ml/min) 100 .70
Urine Calcium/creatinine (mmol/mmol) 0.51 ,0.48
Urinary cyclic AMP excretion (pmol/min) 2700 32006600
doi:10.1371/journal.pone.0034764.t001
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uptake by the main renal phosphate transporter NPT2a
(SLC34A1). Wild type or E68A cDNA were co-expressed with
NPT2a in Xenopus oocytes and phosphate uptake was assessed by
the measurement of sodium-dependent phosphate-induced cur-
rent. Expression of NPT2a alone markedly increased phosphate-
induced current (figure 4A). Co-expression of NPT2a with wild
type NHERF1 further increased phosphate uptake. By contrast
the magnitude of phosphate transport in Xenopus oocytes
expressing the E68A mutant and NPT2a was similar to that
measured in the absence of NHERF1 (figure 4A). We reproduced
these experiments in cultured human epithelial cells (Hela cells) in
culture that do not express endogenous NPT2a or NHERF1 (see
supplementary data). Expression of NPT2a alone in these cells
significantly raised sodium-dependent phosphate uptake above
basal values (figure 4B). Expression of wild type NHERF1
produced an additional increase in sodium-dependent phosphate
transport. However phosphate uptake was similar in Hela cells
expressing NPT2a alone or together with E68A NHERF1 mutant.
Figure 2. Localization of the mutation. A: Sequence analysis of genomic DNA from the patient with NHERF1 mutation. The upper panel shows
the portion of the DNA sequence from the patient with NHERF1 mutation. The sequence can be compared with that obtained in a subject with no
mutation (lower panel). The nucleotide and the amino acid sequences (above and below the horizontal line respectively) are indicated. A vertical
arrow points the mutation. The patient was heterozygous for the mutation. Conservation of the NHERF1 protein sequence surrounding the mutation
site in various species. The amino acid modified by the mutation is highlighted. B: Alignment of human NHERF1 amino acid sequence around the site
of mutation with homologous sequences of NHERF1 in various species. C: Alignment of human NHERF1 amino acid sequence around the site of
mutation with homologous sequences of NHERF2 in various species.
doi:10.1371/journal.pone.0034764.g002
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cAMP accumulation, PKC activity and phosphate uptake inhibition by PTH were measured in opossum kidney (OK) cells transfected with a plasmid
alone or containing either the wild type cDNA of NHERF1 or cDNA from mutant NHERF1. The mutant E68A has been identified in the patient reported
in the present study, the mutants R153Q and E225K have been characterized in a previous study (9). A: Cells were stimulated with PTH 10
28 M. We
present the increase in cAMP synthesis above the values measured in the absence of PTH. Results are means 6 SD of four independent experiments.
The groups were compared with the use of Kruskall-Wallis test (overall P=0.001, * p,0.05 compared to condition in the absence of NHERF1). B: PKC
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NHERF1-NPT2a interaction we performed co-immunoprecipita-
tion experiments in cells expressing tagged NPT2a and wild-type
or mutated NHERF1 proteins. The amount of wild type and
mutated NHERF1 proteins and of NPT2a protein did not differ
between the various experimental conditions (figure 5 middle and
lower panels). Immunoprecipitation of wild-type or mutant
R153Q or E225K NHERF1 proteins co-immunoprecipitated
similar amounts of NPT2a protein. By contrast, immunoprecip-
itation of the E68A protein co-immunoprecipitated only faint
levels of NPT2a protein (figure 5 upper panel).
We assessed the amount of NPT2a protein present at the
plasma membrane by biotinylation experiments in cells transfected
with NPT2a cDNA alone or with a plasmid containing wild-type
or mutant NHERF1 cDNA. The total amount of NPT2a protein
was unchanged by the expression of wild type or E68A mutant
NHERF1 (figure 6). However NPT2a protein abundance at the
cell surface differed between the experimental conditions.
Expression of the wild type NHERF1 was associated with a
significant increase in NPT2a targeting to the plasma membrane
compared to cells expressing NPT2a in the absence of NHERF1
(figure 6). Conversely the expression of the E68A mutant was
associated with a decrease in NPT2a levels at the cell surface
(figure 6).
Discussion
We report here the functional characterization of a previously
unknown mutation in the NHERF1 gene identified in a woman
who had renal lithiasis and a decreased capacity of kidney to
reabsorb phosphate contrasting with serum PTH concentration in
the low normal range. Since the patient had no children and no
relatives alive, we were not able to study the segregation of the
mutation with the phenotype of renal phosphate leak. However
the role of the mutation in the phenotype of the patient is
supported by several lines of evidence: the absence of this mutation
in 224 alleles of subjects with normal TmP/GFR, the uncommon
relationship between serum PTH concentration and TmP/GFR
value, the conservation of the amino acid throughout the
evolution, and, above all, the functional consequences of this
mutation on the expression and activity of the major renal sodium-
activity in cells stimulated with 10
25 Mo r1 0
27 M of PTH. For each PTH concentration used, PTH induced PKC activity did not differ in OK cells
expressing wild type NHERF1 or the E68A mutant. Results are means 6 SD of three independent experiments. C: The inhibitory effect of PTH on
phosphate uptake was determined at two concentrations of PTH (10
25 Mo r1 0
27 M). For each PTH concentration, the magnitude of the PTH-
induced inhibition on phosphate uptake did not differ between OK cells expressing wild type or E68A NHERF1. Results are means 6 SD of three
independent experiments.
doi:10.1371/journal.pone.0034764.g003
Figure 4. Measurement of phosphate transport in cells
expressing the wild type or the E68A mutant NHERF1 together
with the sodium phosphate cotransporter NPT2a. Panel A:
Phosphate-induced current recorded in Xenopus oocytes injected with
water or with either cRNA of NPT2a alone or in association with the
cRNA of the wild type (WT) NHERF1 or the E68A mutant. Results are
means 6 SD, n=9. Overall comparison was performed with the use of
the Kruskall-Wallis test (P,0.0001) then the group expressing NPT2a
alone was compared with other groups with the use of the Mann-
Whitney test (p,0.01). Panel B: Sodium-dependent phosphate uptake
was measured in Hela cells transfected with empty plasmids or with the
plasmid containing the cDNA of NPT2a alone or together with the
cDNA of the wild type or the NHERF1 mutant. Results are means 6 SD,
n=6. Overall comparison was performed with the use of the Kruskall-
Wallis test (P,0.0001) then the group expressing NPT2a alone was
compared with the other groups with the use of the Mann-Whitney test
(* p,0.01 vs NPT2a+WT NHERF1, # p ,0.001 vs NPT2a alone).
doi:10.1371/journal.pone.0034764.g004
Figure 5. Co-immunoprecipitation of NHERF1 with NPT2a in
Hela cells. Hela cells were transfected with a plasmid containing the
cDNA of NPT2a tagged with GFP at its N- extremity. Cells were also
transfected with a plasmid containing the wild type cDNA of NHERF1 or
one mutant (E68A or R153Q or E225K) tagged with Flag. Upper panel:
Flag-tagged-NHERF1 protein was immunoprecipitated by using an anti-
Flag antibody and the immunoprecipitates were probed with anti-GFP
antibodies to detect GFP-tagged-NPT2a on Western blot. Middle panel:
The total expression of GFP-tagged-NPT2a was analyzed in the cell
lysates by anti-GFP Western Blot. Lower panel: Wild type and mutant
Flag-NHERF1 was immunoprecipitated and probed by using anti-Flag
antibodies to compare Flag-NHERF1 immunoprecipitation in the
different conditions.
doi:10.1371/journal.pone.0034764.g005
A Human NHERF1 Mutant Decreases NPT2a Expression
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34764phosphate cotransporter NPT2a when expressed in epithelial cells
and in oocytes. The mutated amino acid is strongly conserved in the
PDZ1 domain of both NHERF1 and NHERF2 of various species
suggesting that it plays a pivotal role in the function of this domain.
The E68A mutation differs from those previously identified by its
localization in the PDZ1 domain and by the mechanism thorough
which it decreases NPT2a expression at the cell surface. The
previously reported mutations of NHERF1were located in the
PDZ2 domain or in the region between PDZ1 and PDZ2 domains.
We have shown that these mutations modify NPT2a expression
onlyinthepresence ofPTH,by increasingcAMP productionbythe
PTH1R and that urinary cAMP excretion was increased in the
patients exhibiting these mutations [9]. In contrast, urinary cAMP
excretionwas normal inthepatient with the E68Amutation and the
mutated protein retained the capacity of decreasing PTH-induced
cAMP production similarly to wild-type NHERF1. These results
suggest that the PDZ1 domain is not crucial for the interaction
between NHERF1 and PTH1R in human. By contrast, our data
show that the PDZ1 domain is critical for the interaction between
NHERF1 and NPT2a. We found that the expression of the wild-
type NHERF1 in human epithelial cells that lack NHERF1
augmented NPT2a location at the plasma membrane. These results
are in line with previous reports showing that re-expressing
NHERF1 in renal proximal tubular cells of NHERF1 null mice
increased NPT2a expression [14]. At variance with wild-type
NHERF1, the E68A mutant failed to increase NPT2a expression at
the surface of human cultured cells and, consequently, did not
enhance phosphate uptake. This lack of effect of the E68A mutant
was likely due to a defect in the interaction between NPT2a and
E68A NHERF1as suggested by the lack of co-immunoprecipitation
of NPT2a with the E68A mutant. In the present study we did not
determine if this interaction was direct or indirect. Experiments
performed in yeast [10] suggested that the C-terminal part of
NPT2a interacts predominantly with the first PDZ domain of
NHERF1. Pull down experiments performed in OK cells
overexpressing NHERF1-PDZ1 showed an interaction between
PDZ1 and NPT2a [15]. However it has not been reported that a
specific disruption of PDZ1 or a mutation in this domain could alter
NPT2a targeting to support the physiological role of PDZ1. Using a
non-natural occurring mutation Weinman demonstrated that
phosphorylation of ser 77 of NHERF1 was mandatory to release
NHERF1 NPT2a interaction, which allows NPT2a internalization
[16]. We report a naturally occurring mutation of a highly
conserved amino acid in PDZ1 that prevents NPT2-NHERF1
binding. The PDZ2 domain might plausibly compensate for an
alteration of PDZ1. However our data show that this defect cannot
be compensated by the presence of PDZ2. These findings
demonstrate that NHERF1 PDZ1 has a central role in the
functional interaction between NHERF1 and NPT2a and in
controlling phosphate homeostasis in humans.
In the present case the data observed in a patient are consistent
with those obtained in a knockout animal model. Indeed the
phenotype of the patient with the E68A mutation, which associates
kidney stones, renal phosphate wasting, a rise in calcitriol
concentration, increased urinary calcium excretion, low PTH levels
and the absence of modification of PTH signaling by the mutant, is
very similar to that observed in NHERF1 knock-out mice [12].
The patient presented with a defect of renal phosphate transport
suggesting that in human renal proximal tubular cells, other
proteins with PDZ domains such as NHERF2 cannot compensate
for the defect of NHERF1. In the rat, NHERF2is not present in the
proximal tubule [17], at variance with the proximal tubule of the
mouse, which expresses both NHERF1 and NHERF2 [18].
Heterozygous and homozygous disruption of the NHERF1 gene
inmicehas been shown to result inan increase in urinary phosphate
excretion suggesting the inability of NHERF2 to compensate for
NHERF1 defects. In humans NHERF2 is only weakly detected in
the proximal tubule [19]. Disruption of NHERF2 gene in mice does
not mimic NHERF1 gene disruption confirming that the functions
of these two proteins are distinct [20].
Co-immunoprecipitation studies suggest that NPT2c may also
interact with NHERF1-PDZ1 in rats. This interaction was not
reproduced in renal cells in culture. NPT2c sequence does not
contain PDZ binding motifs [21]. The mechanism of this
interaction is unknown. We cannot exclude that the mutation
described here could also alter NPT2c-NHERF1 interaction and
NPT2c targeting.
These results, together with those of previous studies (9) indicate
that mutations in the NHERF1 gene can alter renal phosphate
transport by various mechanisms according to the location of the
mutation in the functional domains of the protein. The study
reported here identifies a new mechanism of renal phosphate loss
independent of PTH or FGF23 and establishes the role of the first
PDZ domain of NHERF1 in controlling phosphate homeostasis.
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Figure 6. Effect of mutant NHERF1 on the cell surface
expression of NPT2a assessed by biotinylation experiments.
Hela cells were transfected with GFP-tagged-NPT2a alone or together
with a plasmid containing the cDNA of the wild type NHERF1 or the
E68A mutant. NPT2a proteins labelled with sulfo-NHS-SS-biotin were
revealed by using anti-GFP antibodies. Labeled proteins were isolated
with avidin-agarose beads according to manufacturer’s manual (Pierce).
Proteins eluted from the beads and total cell lysate were loaded on a
SDS gel. Western blot was probed with anti-GFP antibodies. Na+ K+
APTase was used as a loading control and detected with specific
antibodies. The higher panel shows a western blot representative of
four experiments. Lower panel: Statistical analyses of the quantification
of the western blot (n=4). Results are presented as mean 6sd.
Quantification of the surface expression of NPT2a: Anova p=0.038. Post
Hoc test: Tukey-Kramer multiple comparisons test (#:p ,0.05;
*p ,0.01).
doi:10.1371/journal.pone.0034764.g006
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